Clinical Trial

Olaparib in PALB2 Advanced Pancreatic Cancer

Study acronym: PALBOLA
Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2024 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06078787
Lead Sponsor Azienda Ospedaliero-Universitaria di Modena
Conditions Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Enrollment 16 participants
Start Date 2023-08-01
Primary Completion 2025-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-06